The global peritoneal dialysis market size reached USD 18.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 26.5 Billion by 2033, exhibiting a growth rate (CAGR) of 4.16% during 2025-2033. North America leads the market attributed to improved healthcare infrastructure, rising cases of chronic kidney diseases, and increasing adoption of home-based dialysis solutions supporting patient-centered care. The market is being driven by the rising number of dialysis centers worldwide, the increasing government initiatives to promote kidney disease management, the growing adoption of continuous ambulatory peritoneal dialysis (CAPD), and the expanding healthcare infrastructure in developing countries.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 18.0 Billion |
Market Forecast in 2033
|
USD 26.5 Billion |
Market Growth Rate 2025-2033 | 4.16% |
Peritoneal dialysis (PD) represents a type of kidney failure treatment procedure wherein a soft plastic tube or catheter is placed in the abdominal lining or belly through surgery. Once it is positioned, a sterile cleansing fluid is transmitted by the duct that helps filter the blood inside an individual’s body by removing waste products. After a period of time, the liquid and filtered unwanted components flow out of the abdomen and are discarded. PD is differentiated into continuous ambulatory peritoneal dialysis and continuous cycling peritoneal dialysis (CCPD). These approaches offer treatment flexibility, reduce the need to visit dialysis centers, and provide better clinical outcomes, resulting in lesser medications and fewer food restrictions. Apart from this, it can be carried out at home and is needle-free; thus, PD is used by hospitals and healthcare centers to treat kidney failures.
To get more information on this market, Request Sample
Expanding Patient Awareness and Education Initiatives
Increasing awareness about treatment choices for chronic kidney disease is driving the peritoneal dialysis market demand by promoting patient preference for accessible and home-based care. Historically, a lack of patient awareness regarding alternatives to hemodialysis restricted adoption rates. Nonetheless, enhanced educational efforts by healthcare professionals, advocacy organizations, and industry stakeholders are assisting patients in making more informed choices. Awareness initiatives emphasize the therapeutic benefits, lifestyle adaptability, and financial savings linked to peritoneal dialysis, enabling patients to engage actively in their care decisions. Improved training modules and accessible instructional materials enable patients and caregivers to effectively handle the therapy at home, further boosting their confidence in the treatment method. As knowledge about the long-term safety and benefits of peritoneal dialysis grows, an increasing number of people are opting for this treatment instead of traditional alternatives. This movement toward knowledge-based choices is enhancing overall acceptance, improving patient satisfaction, and establishing peritoneal dialysis as a favored treatment option in kidney care.
Growing Preference for Home-Based Dialysis Therapies
Peritoneal dialysis provides patients the ease of performing treatment at home, lowering reliance on hospital appointments and decreasing exposure to medical environments. This independence boosts patient comfort, increases compliance with treatment plans, and leads to an improved overall quality of life. Healthcare professionals and policymakers are promoting home-based options to alleviate strain on dialysis facilities and enhance healthcare resource utilization. The adaptability of peritoneal dialysis enables patients to incorporate treatment into their everyday lives, fostering autonomy while ensuring clinical efficacy. Moreover, improvements in training and patient assistance initiatives are facilitating safer self-management of treatments for individuals. The increasing acceptance of home-based care models corresponds with wider trends in healthcare delivery, encouraging further adoption of peritoneal dialysis as a favored treatment choice.
Supportive Government Policies and Reimbursement Frameworks
Policymakers worldwide are recognizing the growing occurrence of kidney diseases and the need for sustainable treatment solutions, resulting in efforts to enhance dialysis access. Reimbursement programs for peritoneal dialysis, either partial or complete, alleviate financial pressures on patients, making treatment more cost-effective and promoting wider acceptance. As part of these initiatives, in 2025, the Delhi government unveiled plans to introduce 150 new dialysis machines across six government hospitals through the PMNDP and PPP Dialysis Project, offering complimentary dialysis for low-income groups and subsidized treatment for others. Such initiatives enhance current infrastructure and are vital for guaranteeing equitable access to treatment. Additionally, authorities are promoting awareness initiatives and training activities to enhance the confidence of patients and caregivers in home-based treatments. Through the establishment of supportive structures and the provision of incentives, policymakers are enhancing the availability of peritoneal dialysis, promoting its adoption, and serving as a driving force for lasting market expansion.
Increasing Prevalence of Diabetes and Hypertension
The rising incidence of chronic diseases like diabetes and hypertension continues to be a significant factor in the peritoneal dialysis market, as these conditions are primary contributors to chronic kidney disease and end-stage renal failure. As more people face kidney issues, the need for efficient and easily accessible kidney replacement treatments keeps growing. As per the International Diabetes Federation (IDF) Diabetes Atlas (2025), 11.1% of adults between 20 and 79—about 1 in 9—are affected by diabetes, with over 40% unaware of their status, highlighting the critical issue of undiagnosed and unaddressed risks. This growing demand underscores the significance of scalable treatment options like peritoneal dialysis, which offers ongoing therapy and can be administered at home. Its capacity to accommodate personalized schedules and lifestyle adaptability is particularly beneficial for patients with comorbid conditions. With a global emphasis on early intervention and managing chronic diseases, the growing prevalence of diabetes and hypertension are leading to higher adoption of peritoneal dialysis.
Rising Geriatric Population
The growing global elderly population significantly influences the adoption of peritoneal dialysis, as older adults are at greater risk for chronic kidney disease and end-stage renal failure. Elderly individuals frequently gain from home treatments as a result of limited mobility and the ease of self-delivered care. Peritoneal dialysis meets these demands by providing ongoing and adaptable care outside of hospital environments, thus reducing reliance on healthcare facilities. The World Health Organization (WHO) states that by 2030, one in every six individuals globally will be 60 years old or more, and this number is anticipated to hit 2.1 billion by 2050, with those over 80 expected to increase threefold to 426 million. This population change increases the need for accessible, minimally invasive, and patient-focused solutions designed for elderly requirements. With global life expectancy increasing, peritoneal dialysis is set to become essential for providing effective kidney care, fostering long-term market growth and greater acceptance.
Advancements in Dialysis Solution Formulations
Advancements in peritoneal dialysis solution formulations are contributing to the market growth by improving patient safety, comfort, and treatment effectiveness. Contemporary solutions aim to enhance biocompatibility, minimizing irritation and maintaining peritoneal membrane function during extended use. Enhanced formulations also reduce issues like infection or inflammation, boosting patient compliance with treatment. Furthermore, advancements in glucose-derived, amino acid, and icodextrin solutions provide enhanced ultrafiltration effectiveness and superior metabolic results for patients. These developments enable customized therapy, permitting treatment plans to be adjusted to specific patient requirements while ensuring steady effectiveness. As a result, the creation of sophisticated, user-friendly dialysis options promotes greater acceptance of peritoneal dialysis, improves treatment results, and boosts long-term patient contentment. Ongoing advancements in solution chemistry and delivery mechanisms are thus a vital factor bolstering the market growth.
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2025-2033. Our report has categorized the market based on treatment type, product, and end user.
Breakup by Treatment Type:
Breakup by Product:
Breakup by End User:
Breakup by Region:
The report has also provided a comprehensive analysis of the competitive landscape in the global peritoneal dialysis market. Detailed profiles of all major companies have also been provided. Some of the companies covered include:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Treatment Type, Product, End User, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Amecath, Baxter International Inc., Fresenius Medical Care AG & Co. KGaA, Medical Components Inc., Medionics International Inc., Medtronic plc, Merit Medical Systems Inc., Mitra Industries Pvt. Ltd., Newsol Technologies Inc., Nipro Canada (Nipro Medical Corporation), Poly Medicure Limited, Terumo Corporation, Utah Medical Products Inc., etc. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
Key Benefits for Stakeholders: